Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7018992 | NOVO NORDISK INC | Hormone composition |
Sep, 2022
(8 months ago) |
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 26 March, 1999
Treatment: Treatment of atrophic vaginitis due to menopause
Dosage: TABLET;VAGINAL
6
Denmark
5
United States
3
European Union
2
Germany
2
Spain
2
Japan
1
Cyprus
1
Australia
1
Portugal
1
Austria
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6268343 | NOVO NORDISK INC | Derivatives of GLP-1 analogs |
Aug, 2022
(9 months ago) | |
US8114833 | NOVO NORDISK INC | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(2 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8846618 | NOVO NORDISK INC | Stable formulation of modified GLP-1 |
Jun, 2022
(11 months ago) | |
US8846618 (Pediatric) | NOVO NORDISK INC | Stable formulation of modified GLP-1 |
Dec, 2022
(5 months ago) | |
US6268343 (Pediatric) | NOVO NORDISK INC | Derivatives of GLP-1 analogs |
Feb, 2023
(3 months ago) | |
US8579869 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(26 days from now) | |
US8579869 (Pediatric) | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Dec, 2023
(6 months from now) | |
US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(11 months from now) | |
US7762994 (Pediatric) | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Nov, 2024
(1 year, 5 months from now) | |
US8114833 (Pediatric) | NOVO NORDISK INC | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Feb, 2026
(2 years from now) | |
US9265893 | NOVO NORDISK INC | Injection button |
Sep, 2032
(9 years from now) | |
US9265893 (Pediatric) | NOVO NORDISK INC | Injection button |
Mar, 2033
(9 years from now) | |
US9968659 | NOVO NORDISK INC | Liraglutide in cardiovascular conditions |
Jan, 2037
(13 years from now) | |
US9968659 (Pediatric) | NOVO NORDISK INC | Liraglutide in cardiovascular conditions |
Jul, 2037
(14 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Jun 17, 2022 |
Pediatric Exclusivity (PED) | Dec 17, 2022 |
Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient
Market Authorisation Date: 25 January, 2010
Treatment: Method of reducing the risk of cardiovascular death, non-fatal myocardial infarction, and/or non-fatal stroke in adults with type 2 diabetes mellitus and established cardiovascular disease by administ...
Dosage: SOLUTION;SUBCUTANEOUS
22
United States
18
Denmark
14
European Union
7
Spain
7
Japan
7
China
5
Australia
5
Portugal
5
Poland
4
Canada
4
Austria
4
Russia
4
Germany
3
Slovenia
3
Brazil
3
Hungary
2
Korea, Republic of
2
Mexico
1
Israel
1
Croatia
1
Chile
1
Cyprus
1
Philippines
1
Morocco
1
Hong Kong
1
South Africa
1
RS
1
Turkey
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic